Trial Profile
Phase 1a First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs AutoSynVax (Primary) ; QS 21 (Primary)
- Indications Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Agenus
- 01 Dec 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2020 Planned End Date changed from 1 Dec 2020 to 1 Sep 2021.
- 08 Jun 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2021.